CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1,100
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Cryolife (NYSE:CRY) Frequently Asked Questions
What is Cryolife's stock symbol?
Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."
How were Cryolife's earnings last quarter?
Cryolife Inc (NYSE:CRY) released its quarterly earnings results on Thursday, February, 13th. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. The medical equipment provider had revenue of $69.70 million for the quarter, compared to analysts' expectations of $72.95 million. View Cryolife's Earnings History.
When is Cryolife's next earnings date?
What guidance has Cryolife issued on next quarter's earnings?
Cryolife issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $0.15-0.17 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.38. The company issued revenue guidance of $292-298 million, compared to the consensus revenue estimate of $299.19 million.
What price target have analysts set for CRY?
4 Wall Street analysts have issued twelve-month target prices for Cryolife's shares. Their forecasts range from $29.00 to $38.00. On average, they anticipate Cryolife's share price to reach $33.67 in the next year. This suggests a possible upside of 22.3% from the stock's current price. View Analyst Price Targets for Cryolife.
What is the consensus analysts' recommendation for Cryolife?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife.
What are Wall Street analysts saying about Cryolife stock?
Here are some recent quotes from research analysts about Cryolife stock:
- 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (10/23/2019)
- 2. Needham & Company LLC analysts commented, "CRY has undergone a transition into a higher growth company with two major acquisitions since 2015. We believe that it has a full pipeline including 13 new products and indications but we don’t expect these to begin to translate to stronger revenue growth until 2020. And 2019 appears to be a transition year from an earnings and margin perspective. Given all of this, and our belief that CRY shares are fairly valued, we initiate coverage with a Hold rating." (2/27/2019)
Has Cryolife been receiving favorable news coverage?
Press coverage about CRY stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cryolife earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cryolife.
Are investors shorting Cryolife?
Cryolife saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,300,000 shares, an increase of 11.1% from the January 15th total of 1,170,000 shares. Based on an average trading volume of 184,400 shares, the short-interest ratio is currently 7.0 days. Approximately 3.6% of the company's stock are short sold. View Cryolife's Current Options Chain.
Who are some of Cryolife's key competitors?
Some companies that are related to Cryolife include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).
What other stocks do shareholders of Cryolife own?
Who are Cryolife's key executives?
Cryolife's management team includes the folowing people:
- Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
- Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
- Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
- Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
- Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)
Who are Cryolife's major shareholders?
Cryolife's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.47%), ArrowMark Colorado Holdings LLC (2.72%), Loomis Sayles & Co. L P (1.94%), William Blair Investment Management LLC (1.89%), Bank of New York Mellon Corp (1.14%) and Thrivent Financial for Lutherans (0.82%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife.
Which major investors are selling Cryolife stock?
CRY stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Monarch Partners Asset Management LLC, Renaissance Technologies LLC, THB Asset Management, Brasada Capital Management LP, Arizona State Retirement System, Bank of America Corp DE and Pinebridge Investments L.P.. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, David Ashley Lee, James P Mackin, Jean F Holloway, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife.
Which major investors are buying Cryolife stock?
CRY stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Penn Capital Management Co. Inc., State Street Corp, Goldman Sachs Group Inc., Thrivent Financial for Lutherans, Great West Life Assurance Co. Can and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Cryolife.
How do I buy shares of Cryolife?
Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cryolife's stock price today?
One share of CRY stock can currently be purchased for approximately $27.53.
MarketBeat Community Rating for Cryolife (NYSE CRY)
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
